Effect of human amniotic fluid stem cells on kidney function in a model of chronic kidney disease

Sunil K. George, Mehran Abolbashari, Tae Hyoung Kim, Chao Zhang, Julie Allickson, John D. Jackson, Sang Jin Lee, In Kap Ko, Anthony Atala, James J. Yoo

Research output: Contribution to journalArticlepeer-review

Abstract

Kidney disease is a major medical problem globally. Chronic kidney disease (CKD) is a progressive loss of kidney function. It causes accumulation of waste and fluid in the body, eventually resulting in kidney failure as well as damaging other organs. Although dialysis and kidney transplantation have been used as primary treatments for renal disease, dialysis does not restore full renal function, and there is a shortage of donor kidneys for transplantation. Recent advances in cell-based therapies have offered a means to augment and restore renal function. Various types of cells have been tested to evaluate their therapeutic effects on injured kidneys. Among various types of cells, amniotic fluid stem cells (AFSCs) share advantages of both embryonic and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects, which may allow their future therapeutic use as an "off-the-shelf" cell source. AFSC presents advantages of both conventional pluripotent and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects. This study demonstrates that administration of human-derived AFSC facilitates functional and structural improvement in a rat model of CKD, and suggests that cell therapy with AFSC has potential as a therapeutic strategy to recover renal function in patients with CKD. Patients with chronic kidney disease (CKD) have limited treatment options, and renal transplantation is the only definitive treatment method that restores kidney function. However, challenges associated with transplantation, including donor organ shortage, rejection, and life-long immunosuppression, remain a problem. Recently, stem cell-based therapies have been proposed as an alternative approach to augment and restore renal function. In this study, we used human-derived amniotic fluid stem cells (AFSCs) to treat CKD in a rat model and demonstrated that AFSC treatment facilitated positive effects in terms of improvements of renal function.

Original languageEnglish (US)
Pages (from-to)1493-1503
Number of pages11
JournalTissue Engineering - Part A
Volume25
Issue number21-22
DOIs
StatePublished - Nov 2019

Keywords

  • amniotic fluid
  • chronic kidney disease
  • kidney regeneration
  • stem cell therapy

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials

Fingerprint

Dive into the research topics of 'Effect of human amniotic fluid stem cells on kidney function in a model of chronic kidney disease'. Together they form a unique fingerprint.

Cite this